Market Overview:
The global inhalable drugs market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of respiratory diseases, growing demand for dry powder formulations, and rising investments by pharmaceutical companies in research and development (R&D) activities. Based on type, the global inhalable drugs market can be segmented into suspension aerosol, solution aerosol, and dry powder formulation. Of these segments, the suspension aerosol segment is expected to account for the largest share of the global inhalable drugs market in 2018. This segment is projected to grow at a CAGR of 7% during the forecast period from 2018 to 2030. The large share of this segment can be attributed to its high usage rates for treating respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Based on application, the global inhalable drugs market can be divided into respiratory diseases and non-respiratory diseases.
Product Definition:
Inhalable drugs are a type of drug that can be absorbed through the lungs. This type of drug is important because it can be quickly absorbed into the bloodstream, which makes it a fast-acting drug. Inhalable drugs are often used to treat conditions such as asthma and bronchitis.
Suspension Aerosol:
Suspension aerosol is a colloidal system of solid or liquid particles suspended in gas. The most common types of suspension aerosols are gels, sprays and mist. They can be used for direct application to the respiratory tract or by dispersing them in water they can be used for irrigation purposes also.
Suspension Aerosol Inhalation (SAI) drug product was developed as an alternative to conventional solid dosage forms such as tablets.
Solution Aerosol:
Solution aerosol is a type of inhalable drug delivery system that consists of fine solid particles suspended in a liquid. The drug is released gradually over an extended period, which allows the body to absorb the drug at a suitable rate. Solution aerosols are preferred for slow-release or targeted release formulations as they offer several advantages such as controlled release and efficient dose coverage.
Application Insights:
The respiratory diseases segment dominated the global inhalable drugs market in 2017. This can be attributed to high prevalence of asthma, COPD and other lung diseases coupled with increasing usage of long-acting bronchodilators for the treatment of such disorders. For instance, according to data published by Global Asthma Report in 2018, around 300 million people across the world suffer from asthma. In addition, around 50 million people are diagnosed with COPD which is a major cause of mortality as well as disability worldwide.
Non-respiratory diseases segment is expected to witness lucrative growth over the forecast period owing to growing incidence rate and awareness related campaigns against these conditions especially diabetes mellitus type 2 which accounts for approximately 90%of non-respiratory disease cases globally. For instance, according to WHO¢â‚¬â„¢s estimates about 1/3rdto 1/2nd population of U.S.
Regional Analysis:
North America dominated the global inhalable drugs market in 2017 owing to favorable reimbursement policies, increasing prevalence of COPD and asthma, and rising awareness about these therapies. In addition, presence of major players such as Teva Pharmaceuticals USA Inc.; Merck & Co., Inc.; BMS; Allergan Plc; and Johnson & Johnson Services, Inc. is expected to drive growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period due to growing geriatric population base coupled with an increase in chronic respiratory diseases burden in this region. Moreover, economic development has led to improvement in healthcare infrastructure which will further boost revenue generation from inhalable drugs over the next eight years (from 2018’to 2030).
Growth Factors:
- Increasing prevalence of respiratory diseases: The global inhalable drugs market is expected to grow at a CAGR of 5.5% during the forecast period due to the increasing prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and tuberculosis. Inhalable drugs are used for the treatment of these diseases as they provide quick relief from symptoms and improve patient outcomes.
- Technological advancements: The development of novel inhalation devices that can deliver drugs directly to the lungs is expected to drive market growth during the forecast period. These devices are easy-to-use, portable, and help in reducing drug wastage. Additionally, technological advancements in drug delivery systems are helping in improving patient compliance rates with therapy regimens.
- Growing demand for targeted therapies: Inhalable drugs offer an advantage over traditional oral medications as they can provide targeted therapy directly to the site of action within the lungs minimizing systemic side effects associated with oral medications administration route . This is driving demand for inhalable drugs among patients suffering from respiratory disorders such as asthma and COPD .
Scope Of The Report
Report Attributes
Report Details
Report Title
Inhalable Drugs Market Research Report
By Type
Suspension Aerosol, Solution Aerosol, Dry Powder Formulation
By Application
Respiratory Diseases, Non-respiratory Diseases
By Companies
NanoDerma, Pfizer, Aradigm Corporation, Alkerme, Dura Pharmaceuticals, AeroGen and Inhale Therapeutic Systems, NanoDerma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Inhalable Drugs Market Report Segments:
The global Inhalable Drugs market is segmented on the basis of:
Types
Suspension Aerosol, Solution Aerosol, Dry Powder Formulation
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Respiratory Diseases, Non-respiratory Diseases
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- NanoDerma
- Pfizer
- Aradigm Corporation
- Alkerme
- Dura Pharmaceuticals
- AeroGen and Inhale Therapeutic Systems
- NanoDerma
Highlights of The Inhalable Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Suspension Aerosol
- Solution Aerosol
- Dry Powder Formulation
- By Application:
- Respiratory Diseases
- Non-respiratory Diseases
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Inhalable Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Inhalable drugs are medications that can be inhaled through the nose. They are often used to treat conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other respiratory problems. Inhalable drugs work by delivering medication directly to the lungs, where it can reach more of the body's cells and tissues.
Some of the major companies in the inhalable drugs market are NanoDerma, Pfizer, Aradigm Corporation, Alkerme, Dura Pharmaceuticals, AeroGen and Inhale Therapeutic Systems, NanoDerma.
The inhalable drugs market is expected to register a CAGR of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Inhalable Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Inhalable Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Inhalable Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Inhalable Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Inhalable Drugs Market Size & Forecast, 2018-2028
4.5.1 Inhalable Drugs Market Size and Y-o-Y Growth
4.5.2 Inhalable Drugs Market Absolute $ Opportunity
Chapter 5 Global Inhalable Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Inhalable Drugs Market Size Forecast by Type
5.2.1 Suspension Aerosol
5.2.2 Solution Aerosol
5.2.3 Dry Powder Formulation
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Inhalable Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Inhalable Drugs Market Size Forecast by Applications
6.2.1 Respiratory Diseases
6.2.2 Non-respiratory Diseases
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Inhalable Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Inhalable Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Inhalable Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Inhalable Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Inhalable Drugs Market Size Forecast by Type
9.6.1 Suspension Aerosol
9.6.2 Solution Aerosol
9.6.3 Dry Powder Formulation
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Inhalable Drugs Market Size Forecast by Applications
9.10.1 Respiratory Diseases
9.10.2 Non-respiratory Diseases
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Inhalable Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Inhalable Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Inhalable Drugs Market Size Forecast by Type
10.6.1 Suspension Aerosol
10.6.2 Solution Aerosol
10.6.3 Dry Powder Formulation
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Inhalable Drugs Market Size Forecast by Applications
10.10.1 Respiratory Diseases
10.10.2 Non-respiratory Diseases
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Inhalable Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Inhalable Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Inhalable Drugs Market Size Forecast by Type
11.6.1 Suspension Aerosol
11.6.2 Solution Aerosol
11.6.3 Dry Powder Formulation
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Inhalable Drugs Market Size Forecast by Applications
11.10.1 Respiratory Diseases
11.10.2 Non-respiratory Diseases
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Inhalable Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Inhalable Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Inhalable Drugs Market Size Forecast by Type
12.6.1 Suspension Aerosol
12.6.2 Solution Aerosol
12.6.3 Dry Powder Formulation
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Inhalable Drugs Market Size Forecast by Applications
12.10.1 Respiratory Diseases
12.10.2 Non-respiratory Diseases
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Inhalable Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Inhalable Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Inhalable Drugs Market Size Forecast by Type
13.6.1 Suspension Aerosol
13.6.2 Solution Aerosol
13.6.3 Dry Powder Formulation
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Inhalable Drugs Market Size Forecast by Applications
13.10.1 Respiratory Diseases
13.10.2 Non-respiratory Diseases
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Inhalable Drugs Market: Competitive Dashboard
14.2 Global Inhalable Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 NanoDerma
14.3.2 Pfizer
14.3.3 Aradigm Corporation
14.3.4 Alkerme
14.3.5 Dura Pharmaceuticals
14.3.6 AeroGen and Inhale Therapeutic Systems
14.3.7 NanoDerma
